Obinutuzumab Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Obinutuzumab Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
360
Registered trials
453
Result records
2
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Obinutuzumab can convert its Monoclonal antibody profile and CD20 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Obinutuzumab (query alias: obinutuzumab) |
|---|---|
| Modality / target | Monoclonal antibody; CD20; CD20 inhibitors, ADCC, CD20-directed cytolytic effects |
| Highest global status | Approved |
| Originator | Roche Glycart AG |
| Active developers | F. Hoffmann-La Roche Ltd., Hoffmann-La Roche, Inc., Roche Registration GmbH |
The MCP disease footprint includes Lupus Nephritis, CD20 Positive B-Cell Chronic Lymphocytic Leukemia, CD20 positive Follicular Lymphoma. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| ChiCTR2600126314 | Phase 4 | Not yet recruiting | 24 | Complete response rate, CRR |
| NCT07674810 | Phase 2 | Not yet recruiting | 40 | Safety and Adverse Events (AEs) |
| NCT07634289 | Phase 2 | Not yet recruiting | 40 | Complete Response Rate After Radiotherapy and Glofitamab Treatment |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
A Single-center, Phase 2 Open-label Trial Evaluating the Efficacy and Safety of OBINUTUZUMAB in Treatment of Immunosuppression-dependent or Immunosuppression/Treatment-resistant Primary FSGS, or Contraindication/Patient Refusal to Take High Dose Corticosteroids
Phase 2; n=20; evaluation: not stated. Reported fields: Proteinuria at baseline(Median) = 10.7 g/d (Inter-Quartile Range, 7.5 - 13.7); -; -
OBINUTUZUMAB DEMONSTRATES CONSISTENT EFFICACY IN LUPUS NEPHRITIS INDEPENDENT OF BASELINE TYPE 1 INTERFERON GENE SIGNATURE: POST-HOC EXPLORATORY ANALYSES OF THE PHASE III REGENCY TRIAL
Phase 3; n=271; evaluation: Positive. Reported fields: CRR(Week 76) = 32.5 % ; CRR(Week 76) = 35.6 % ; CRR(Week 76) = 46.7 %
THE IMPACT OF OBINUTUZUMAB ON REMISSION AND LOW DISEASE ACTIVITY IN ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS: ADDITIONAL RESULTS OF THE PHASE III ALLEGORY TRIAL
Phase 3; n=303; evaluation: Positive. Reported fields: DORIS(52 Week) = 13.8 % ; DORIS(52 Week) = 35.1 %
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Obinutuzumab addresses Lupus Nephritis, CD20 Positive B-Cell Chronic Lymphocytic Leukemia, CD20 positive Follicular Lymphoma. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Monoclonal antibody—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 2 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2012-11-27 | Chugai Pharmaceutical Co-Development and Co-Marketing Agreement with Nippon Shinyaku for the Glycoengineered Type II Anti-CD20 Monoclonal Antibody, "GA101" | Phase 3 | Financial terms not disclosed |
| 2008-11-02 | Biogen Idec Elects to Participate with Genentech in the Development and Commercialization of a Next Generation Anti-CD20 Molecule | Phase 3 | US$31.5M upfront |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Therapeutic combination of an AKT inhibitor, a BCL-2 inhibitor, and an Anti-CD20 antibody”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Class crowding and differentiation versus other PD-(L)1/VEGF agents
- Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
- Biomarker strategy, indication selection, and head-to-head endpoint execution
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
